Leerink upgrades NeoGenomics to Outperform, raises target to $25

As previously reported, Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a price target of $25, up from $12. The company delivers on its one-stop shop business model in oncology diagnostics and is getting back on track, in the firm’s view, with strong momentum, profitability, and attractive valuation that cannot be ignored.